Call: +7 771 977 66 65, +7 705 421 2277
Sign in or Register
My basket

Astana Biomed Group, an authorized Abcam distributor in Central Asia

Abiomed homepage

  • Categories
    Signal Transduction
    Cancer
    Epigenetics and Nuclear Signaling
    Immunology
    Cell Biology
    Cardiovascular
    Neuroscience
    Tags & Cell Markers
    Kits/ Lysates/ Other
    Developmental Biology
    Microbiology
    Biochemicals
    Secondary antibodies
    Isotype/Loading Controls
    Antibody Arrays
  • About us
  • Partners
  • Contact
    Address

    Saryarka 32, 18, 010000, Astana city, Kazakhstan

    Telephone +7 771 977 66 65, +7 705 421 2277

    Email

    laboratory@ctlab.kz, orders@abiomed.kz

Back to category

Human IL6ST (CD130/gp130) knockout A549 cell pellet (ab279246)

Price and availability

670 ₸

Availability

Order now and get it on Tuesday March 09, 2021

Human IL6ST (CD130/gp130) knockout A549 cell pellet (ab279246)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)

You may also be interested in

Product image
Anti-MUC2 antibody [EPR23479-47] - BSA and Azide free (ab272706)
Product image
Anti-Lin28B antibody (ab264334)
Cytosine, Nucleoside (ab146257)
Product image
Human ICAM1 knockout HeLa cell pellet (ab278920)

Properties

  • Storage instructions

    Store at -80°C. Please refer to protocols.
  • Components 1 kit
    Human IL6ST knockout A549 cell pellet 1 vial
    Human wild-type A549 cell pellet 1 vial
  • Research areas

    • Cell Biology
    • Apoptosis
    • Intracellular
    • Associated Proteins
    • Immunology
    • Cell Type Markers
    • CD
    • Cytokines
    • Signal Transduction
    • Adapters
    • Transmembrane
    • Cancer
    • Signal transduction
    • Other
    • Cardiovascular
    • Atherosclerosis
    • Apoptosis
    • Cardiovascular
    • Heart
    • Apoptosis
    • Cardiovascular
    • Heart
    • Hypertrophy
    • Other
  • Cell type

    epithelial
  • Disease

    Carcinoma
  • STR Analysis

    Amelogenin X,Y D5S818: 11 D13S317: 11 D7S820: 8, 11 D16S539: 11, 12 vWA: 14 TH01: 8,9.3 TPOX: 8,11 CSF1PO: 10, 12

Images

  • Western blot - Human IL6ST (CD130/gp130) knockout A549 cell pellet (ab279246)
    Western blot - Human IL6ST (CD130/gp130) knockout A549 cell pellet (ab279246)

    Lane 1: Wild-type A549 cell lysate (20 µg)

    Lane 2: IL6ST knockout A549 cell lysate (20 µg)

    Lanes 1-2: Merged signal (red and green). Green - ab217671 observed at 130 kDa. Red - loading control ab7291 observed at 50 kDa.

    ab217671 Anti-CD130 (gp130) antibody [EPR21732] was shown to specifically react with CD130 (gp130) in wild-type A549 cells. Loss of signal was observed when knockout cell line ab266938 (knockout cell lysate ab257207) was used. Wild-type and CD130 (gp130) knockout samples were subjected to SDS-PAGE. ab217671 and Anti-alpha Tubulin antibody [DM1A] - Loading Control (ab7291) were incubated overnight at 4°C at 1 in 1000 and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

  • Sanger Sequencing - Human IL6ST (CD130/gp130) knockout A549 cell pellet (ab279246)
    Sanger Sequencing - Human IL6ST (CD130/gp130) knockout A549 cell pellet (ab279246)

    Allele-1: 4 bp deletion in exon4

     

  • Sanger Sequencing - Human IL6ST (CD130/gp130) knockout A549 cell pellet (ab279246)
    Sanger Sequencing - Human IL6ST (CD130/gp130) knockout A549 cell pellet (ab279246)

    Allele-2: 1 bp insertion in exon4

     

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Get resources and offers direct to your inbox Sign up
© 2021 Astana Biomed Group LLP. All rights reserved.